{"metadata": {"source": "pubchem", "title": "Fentanyl | C22H28N2O | CID 3345 - PubChem", "description": "Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/3345", "drug": "Fentanyl", "cid": 3345, "char_count": 196495, "word_count": 26843, "doc_id": "doc_16", "num_chunks": 282, "chunk_id": "16::chunk_22", "document_index": 16, "latency_s": 1.657663699996192, "prompt_toks": 49722, "completion_toks": 89, "relevance_score": 0.071202725}, "content": "Drug: Fentanyl | cid: 3345\nSource: pubchem | Source description: Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    FDA Label\n\nEffentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. , , BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. , , Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. ,\n\n7.2 Drug Classes\n\nBreast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Anesthetics, Intravenous; Opiates\n\n7.3 Drug Transformations\n\nFentanyl has known transformation products that include Norfentanyl.\n\nS66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448\n\n7.4 FDA Medication Guides\n\n1 of 7\n\nView All\n\nDrug\n\nActive Ingredient\n\n\n                    Context: \n                    This excerpt provides detailed information regarding the FDA-approved label for Effentora, a fentanyl-based medication used to treat breakthrough cancer pain in opioid-tolerant adults, including its indications, drug classes, known transformation product Norfentanyl, and related medication guides. It is relevant to the comprehensive chemical and pharmacological data on fentanyl presented in the full document, highlighting clinical usage, drug transformations, and regulatory aspects essential for research and medical reference.\n                "}
{"metadata": {"source": "pubchem", "title": "Fentanyl | C22H28N2O | CID 3345 - PubChem", "description": "Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/3345", "drug": "Fentanyl", "cid": 3345, "char_count": 196495, "word_count": 26843, "doc_id": "doc_16", "num_chunks": 282, "chunk_id": "16::chunk_35", "document_index": 16, "latency_s": 1.4108739999937825, "prompt_toks": 49677, "completion_toks": 77, "relevance_score": 6.156764e-05}, "content": "Drug: Fentanyl | cid: 3345\nSource: pubchem | Source description: Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    /BOXED WARNING/ WARNING: ABUSE POTENTIAL. Oral transmucosal fentanyl citrate contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. Oral transmucosal fentanyl citrate can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing oral transmucosal fentanyl citrate in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion. Because of the risk for misuse, abuse, addiction, and overdose, oral transmucosal fentanyl citrate is available only through a restricted program, required by the Food and Drug Administration, called a Risk Evaluation and Mitigation Strategy (REMS). Under the Transmucosal Immediate Release Fentanyl (TIRF) REMS Access program, outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors must enroll in the program. /Fentanyl\n\n\n                    Context: \n                    This excerpt is a critical safety warning section highlighting the abuse potential, controlled substance classification, and regulatory restrictions for oral transmucosal fentanyl citrate. It emphasizes the drug's risks of misuse, addiction, and overdose, and describes the restricted access program (REMS) required by the FDA. Its placement within the full document underscores fentanyl's serious safety concerns and regulatory controls.\n                "}
{"metadata": {"source": "pubchem", "title": "Fentanyl | C22H28N2O | CID 3345 - PubChem", "description": "Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/3345", "drug": "Fentanyl", "cid": 3345, "char_count": 196495, "word_count": 26843, "doc_id": "doc_16", "num_chunks": 282, "chunk_id": "16::chunk_35", "document_index": 16, "latency_s": 1.4108739999937825, "prompt_toks": 49677, "completion_toks": 77, "relevance_score": 6.156764e-05}, "content": "Drug: Fentanyl | cid: 3345\nSource: pubchem | Source description: Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    /BOXED WARNING/ WARNING: ABUSE POTENTIAL. Oral transmucosal fentanyl citrate contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. Oral transmucosal fentanyl citrate can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing oral transmucosal fentanyl citrate in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion. Because of the risk for misuse, abuse, addiction, and overdose, oral transmucosal fentanyl citrate is available only through a restricted program, required by the Food and Drug Administration, called a Risk Evaluation and Mitigation Strategy (REMS). Under the Transmucosal Immediate Release Fentanyl (TIRF) REMS Access program, outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors must enroll in the program. /Fentanyl\n\n\n                    Context: \n                    This excerpt is a critical safety warning section highlighting the abuse potential, controlled substance classification, and regulatory restrictions for oral transmucosal fentanyl citrate. It emphasizes the drug's risks of misuse, addiction, and overdose, and describes the restricted access program (REMS) required by the FDA. Its placement within the full document underscores fentanyl's serious safety concerns and regulatory controls.\n                "}
